Articles On BARD1 Life Sciences (ASX:BD1)

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

When it comes to cancer diagnostics, the ‘tried and trusted’ methods are often not the best ones, but merely the techniques clinicians are familiar with. For the ASX-listed INOVIQ (ASX:IIQ), the field is ripe for disruption and the company...

Disclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and associated entities, own 13,631,579 ALA shares. S3 Consortium Pty Ltd has been engaged by ALA to share our commentary on the progress of our in...

Local stocks end up posting a solid session on Monday, following some steady gains on Wall Street on Friday night. Things looked shaky early, but the ASX 200 steadied in afternoon trade to finish around 0.5% higher. ASX 200 tech stocks rose...

The Inoviq Ltd (ASX: IIQ) share price is racing higher during early Friday afternoon. This comes after the medical diagnostics company announced it has secured a new patent for diagnosing lung cancer. At the time of writing, Inoviq shares...

Video technology company BirdDog Technology (ASX:BDT) completed an ASX listing less than a week before Christmas. The firm offers solutions that enhance the quality, speed and flexibility of video allowing high-definition video to be delive...

The BARD1 Life Sciences Limited (ASX: BD1) share price isn’t going anywhere on Thursday. In fact, the BARD1 share price has vanished completely from the ASX boards today. Where is the BARD1 share price? The good news is that nothing bad ha...

ASX recovered some lost ground in arvo trade but still finished 0.54% down, as markets continue to be shaken by the discovery of the omicron variant of COVID-19 and falling oil prices. Resources and tech managed to finish in the green – by...

The BARD1 Life Sciences Ltd (ASX: BD1) share price was a very strong performer on Friday. At one stage, the diagnostics company’s shares were up as much as 44% to $1.43. The BARD1 share price gave back some of these gains but ultimately en...

The ASX had a positive finish to the week although it is in negative territory for the week. The ASX 200 closed at 7,443 points which is up 0.83% from yesterday but slightly down from the 7,457 mark it closed at last Friday. Today, the only...

The BARD1 Life Sciences Ltd (ASX: BD1) share price is rocketing on Friday morning. This comes after the medical diagnostics company announced it has secured a new patent. At the time of writing, BARD1 shares are shooting 16.16% higher to $...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Our new business model is to research, analyse, and invest in up and coming small cap ASX-listed biotech stocks that we believe have a high chance of success. We then share our research and commentary along our investment journey with our r...

The ASX 200 health stocks index (XHJ) has lifted by 0.46% at the time of writing, compared to the broader ASX 200 index which rose by 0.73%. Mergers and acquisitions were very much the order of the day in the Health sector today. The countr...

The BARD1 Life Sciences Ltd (ASX: BD1) share price has walked through today’s session in the green. Before the open, BARD1 updated investors on a significant milestone in the development of its ELISA diagnostics test. Let’s investigate fu...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

The BARD1 Life Sciences Ltd (ASX: BD1) share price is slipping after the company released its latest quarterly report. BARD1’s quarterly activities report for the 3 months ended 30 June details a seemingly good period for the company. Howe...

Chairman Dr Geoff Cumming said: “The capital raising was strongly supported by new and existing institutional and sophisticated investors with a deep understanding of the biotechnology sector and importance of early cancer detection on pati...

In late afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a small decline. At the time of writing, the benchmark index is down slightly to 7,385.7 points. Four ASX shares that are falling more than mos...

The BARD1 Life Sciences Ltd (ASX: BD1) share price is deep in negative territory late this afternoon. This comes after the medical diagnostics company provided investors with an update on its capital raising efforts. At the time of writing...

The BARD1 Life Sciences Ltd (ASX: BD1) share price is frozen today as the company prepares to announce news of a capital raise. Trading of its shares will be halted until it either releases an announcement or the ASX opens on Friday mornin...

Preclinical stage company, Nyrada (ASX:NYR), announced major progress today in the fight on cholesterols, reporting encouraging efficacy results from the second pre-clinical vivo study of NYX-PCSK9i. The study shows that when given in combi...

The BARD1 Life Sciences Ltd (ASX: BD1) share price has been a strong performer on Tuesday morning. In early trade, the diagnostics company’s shares are up 10% to $2.14. This means the BARD1 share price is now up over 200% since the start o...

Tech gains on Wall Street amid fears of COVID-19 spike Growth stocks were the winners on Wall Street overnight, at the expense of cyclical stocks as fears about a new wave of COVID-19 cases spooked markets. The S&P 500 and tech heavy Na...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Summary The S&P/ASX200 plummets 1.70% to 6945 amid broad-based selling. All 11 sectors were trading in red, while energy was the top laggard, falling over 2.5%. EML Payments was the top percentage loser on ASX, dropping over 37%...

BARD1 Life Sciences Ltd (ASX: BD1) shares are galloping into the green today. This follows the company announcing it is presenting EXO-NET data at the International Society for Extracellular Vesicles conference. At the time of writing, the...

Biotech company BARD1 Life Sciences (ASX:BD1) just launched its latest product, RUO EXO-NET, at the International Society of Extracellular Vesicles (ISEV) Annual Meeting today. The EXO-NET is a technology that allows fast, accurate and scal...

Summary Oncology firm Telix Pharmaceuticals has entered into an exclusive commercial distribution agreement to distribute its product in the German market. Proteomics has secured a significant contract for pharmacokinetic testing, whil...

The positive start to the week has continued for ASX stocks. The ASX 200 closed at 7,066, 0.60 per cent higher than yesterday although it is still 100 points off its record high reached in February 2020 and last week. Meanwhile, the ASX Eme...

A series of ASX announcements has attracted investors to the biotech sector today, lifting the share prices of some of its players. The buying frenzy has also lifted the broader health sector by as high as 1 per cent earlier today, but is c...

Summary PPK Group’s 48% owned subsidiary, Li-S Energy Limited has developed a revolutionary lithium sulphur battery. Eastern Iron has completed its entitlement offer, raising up to approximately AU$1,072,370. BOD Australia has announc...

The BARD1 Life Sciences Ltd (ASX: BD1) share price is in the green today, adding to strong yearly gains, after the company released positive results from its autoantibody assay. After touching an intraday high of $3.50 in early trade today...

Source: Ratanapon Srisuneton, Shutterstock Summary Universal Biosensors has entered into exclusive agreements for the commercialisation and development of its biosensors. Avecho has received ethics approval to conduct an Australian Ph...

The BARD1 Life Sciences Limited (ASX: BD1) share price rocketed 9.71% on opening today after the company signed an agreement with the University of Liverpool. The agreement is the first step towards licensing BARD1’s blood test, which the...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The ASX he...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Source:WHYFRAME, Shutterstock Summary Huge market volatility has been observed in 2021 so far amid the tug of war between surging COVID-19 cases and progress in economic recovery. Volatility is expected to continue over the coming day...

Source: Blue Planet Studio, Shutterstock Summary Oncology player Race Oncology has collaborated with the University of Newcastle for its preclinical research program to study Bisantrene in melanoma. Leading Australian diagnostics play...

Source: CI Photos, Shutterstock Summary BARD1 Life Sciences unveiled encouraging results from a pancreatic cancer pilot study. The results validate potential for RUO EXO-NET™ product for capture of exosomes, anticipated to be launched...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Source: CI Photos, Shutterstock Summary ASX-listed leading immunotherapy developer Immutep Limited entered into a second clinical trial collaboration with Merck & Co’s subsidiaries. Diagnostic company BARD1 Life Sciences revealed...

Bard1 Life Sciences (ASX:BD1) has surged again with news its technology can detect another cancer. In the past few weeks shares ... Read More The post Bard1 caps off 600pc+ in 6 weeks proving it can detect another type of cancer appeared fi...

The BARD1 Life Sciences (ASX: BD1) share price is on watch today after positive results from the evaluation of its EXO-NET product in pancreatic cancer.  Let’s take a closer look at the announcement and what this means for the BARD1 share...

BARD1 Life Sciences Ltd (ASX: BD1) shares are climbing today following a favourable outcome for the company’s hTERT test. At the time of writing, the BARD1 share price has leapt 6.34% to $3.86.  Let’s take a closer look at what the diagnos...

In February, ASX fintech stocks were winners, losers and winners again. The benchmark ASX 200 index made a 1 per cent gain for month – despite a late month drop — driven largely by favourite fintech Zip (ASX:Z1P) +43%, as well as Virgin Mon...

The small-cap space is always filled with explosive ASX shares looking to emerge as the next big thing. Here are the small-cap ASX shares that made headlines in February.  1. Province Resources Ltd (ASX: PRL)  The Province Resources share...

The BARD1 Life Sciences Ltd (ASX: BD1) share price fell off its perch today after the company announced that legal proceedings have commenced against it. Consequently, shareholders have been rattled by the news, leading to a selloff in the...

BARD1 Life Sciences (ASX:BD1) shares have slipped, after news its two founders have sued the cancer diagnostics company over their ... Read More The post BARD1 founders sue company over performance rights appeared first on Stockhead.